An international team engineered a bacterial strain that overcomes long‑standing biosynthetic bottlenecks in doxorubicin production, the consortium reported in Nature Communications. The redesigned pathway and strain engineering substantially increased natural product yields, addressing supply and cost constraints for a cornerstone chemotherapy agent. The advance revives microbial production as a practical route for complex anthracycline antibiotics and could reduce dependence on multi‑step chemical syntheses. Biomanufacturing and CDMO partners may fast‑track scale‑up studies; regulatory and CMC teams will evaluate impurity profiles and process robustness as companies consider clinical‑grade manufacture and commercial supply chains.